oral tirzepatide development status Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study | Diabetologia Shifting the Scales: Tirzepatide's Breakthrough

Every treatment decision should be based on your healthcare providers evaluation rather than anonymous recommendations found online

Abstract Recent studies point to the effectiveness of novel treatments that address physiological abnormalities associated with autism spectrum disorder (ASD)

Meet the weight-management clinical criteria (measured at the time GLP-1 therapy was first started): BMI of 35 or higher, or BMI of 30 or higher with heart failure (preserved ejection fraction), uncontrolled high blood pressure, or chronic kidney disease (stage 3a or above), or BMI of 27 or higher with prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease

A multidisciplinary Scientific Committee, consisting of two endocrinologists, a family physician, an internist, and a cardiologist, was established

Originally designed to treat diabetes and obesity, these medications mimic a hormone naturally produced in the small intestine and the brain